Pathway Function MASP-1

Total Page:16

File Type:pdf, Size:1020Kb

Pathway Function MASP-1 The Pro-Factor D Cleaving Activity of MASP-1/-3 Is Not Required for Alternative Pathway Function This information is current as Søren E. Degn, Jens C. Jensenius and Steffen Thiel of September 25, 2021. J Immunol 2014; 192:5447-5448; ; doi: 10.4049/jimmunol.1400777 http://www.jimmunol.org/content/192/12/5447 Downloaded from References This article cites 8 articles, 7 of which you can access for free at: http://www.jimmunol.org/content/192/12/5447.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 25, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2014 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Th eJournal of Letters to the Editor Immunology The Pro-Factor D Cleaving Activity Furthermore, our observation (1) of marked alternative path- of MASP-1/-3 Is Not Required for way activity in the MASP-1/-3 deficient human suggested that any such backup pathways were highly functional, calling Alternative Pathway Function into question the purported essential role of MASP-1/-3. Recently, fresh observations have shed new light on the basis e recently reported in The Journal of Immunology of this controversy, prompting us to readdress the issue in this (1) the presence of a functional alternative path- letter. In their recent article, Ruseva and colleagues (7) dem- W way in a human patient with Malpuech–Michels– onstrated that MASP-1 and MASP-3 are not essential for Mingarelli–Carnevale (3MC) syndrome caused by a genetic activation of the complement system via the alternative path- defect in the MASP1 gene. This defect abolished the pro- way in vivo [(7); murine complement]. However, they noted duction of all three splice products of this gene: mannan- that this occurred in the absence of detectable mature fD [(7); binding lectin (MBL)–associated serine proteases (MASP)-1 murine complement]. This reconciles the previous seemingly and MASP-3, and MBL-associated protein of 44 kDa disparate findings, as it confirms both the observation of Downloaded from (MAp44) (human complement). Takahashi et al. (4) on the role of MASP-1/-3 in cleaving Our paper generated debate because the findings directly profD and our observation of a functioning alternative path- conflicted with results obtained in a mouse model of complete way in the absence of MASP-1/-3. Two possible scenarios MASP1 deficiency (2, 3). In 2010 Takahashi and colleagues present themselves: either undetectable but catalytically func- (4) reported in the Journal of Experimental Medicine that tional levels of mature fD are generated during alternative pathway activation via the bypass pathways suggested by MASP-1 was the protease responsible for cleaving profactor D http://www.jimmunol.org/ (profD) and thus essential for the presence of mature, active Takahashi and colleagues; or, in contrast to what was previ- fD in the blood [(4); murine complement]. Thus, in a mouse ously reported [(8); human complement], profD has sig- model of genetic deficiency of all three Masp1 gene products, nificant activity toward the fBC3(H2O) substrate. Further Takahashi et al. (4) reported complete deficiency of the al- studies are needed to answer this question. ternative pathway. They determined this to be caused by a Meanwhile, the discrepancy between results of Ruseva et al. complete absence of mature, active fD in the Masp1 knockout [(7); murine complement] and Takahashi et al. [(4); murine serum, and demonstrated that recombinant murine MASP-1 complement] regarding alternative pathway activity in the could cleave profD, rescuing alternative pathway activation in Masp1 knockout mouse serum prompted us to reexamine this vitro. The group followed up on these findings (5) reporting activity. We report in this letter that the difference arises from by guest on September 25, 2021 that MASP-3 could also cleave profD, and in addition, at low the use of different buffer systems. At physiological ionic efficiency, factor B to Bb [(5); murine complement]. The strength, alternative pathway activity is observed, albeit at a suggestion of an essential role of MASP-1/-3 in alternative lower level than in wild type mice, thus confirming the recent pathwayfunctionwascorroboratedbyastudyusingthe results of Ruseva et al. [(7); murine complement] (Fig. 1A, 1B). murine anti-collagen Ab-induced model of inflammatory Conversely, the high ionic strength buffer used by Takahashi arthritis, which is known to be sensitive to alterations in the et al. [(4); murine complement] suppresses the weaker alter- alternative pathway [(6); murine complement]. native pathway activity of the Masp1 knockout mouse to Surprisingly, our results (1), based on the 3MC syndrome background levels (Fig. 1C). This suggests that either the patient and in vitro studies with recombinant human MASP-1, interaction of backup enzymes with profD or the profD in- indicated that in humans neither MASP-1 nor MASP-3 are teraction with fBC3(H2O) substrate is sensitive to high ionic required for alternative pathway function [(1); human com- strength. plement]. It was suggested that the activity we observed was Regarding the discrepancy between the role of MASP-1/-3 due to backup pathways, with thrombin, kallikrein, and plas- in vivo in the anti-collagen Ab-induced arthritis model of Banda min being able to cleave profD (3). Because of natural variation et al. [(6); murine complement] and in the fH deficient model in alternative pathway hemolytic activity and the availability of of Ruseva et al. [(7); murine complement], we also attempt to only a single deficient human, we could not determine whether offer some insight. The former model is dependent on the al- MASP-1/-3 deficiency caused a quantitative deficiency, but ternative pathway for initiation and propagation of injury, and simply noted the existence of significant alternative pathway due to the weaker alternative pathway activation in the Masp1 activity, indicating that mature fD was indeed present in the knockout, significant protection is observed. The latter model absence of MASP-1/-3 (2). is based on the absence of a crucial regulator of the alternative The issue remained that the complete absence of alternative pathway: factor H. In this scenario, the lower level alternative pathway activity in the MASP-1/-3 deficient mouse was not pathway activity in Masp1 knockouts is sufficient to initiate reconcilable with the existence of the proposed backup pathways. formation of C3 convertase, which in the absence of factor H forms an unregulated positive amplification loop. Hence, the two scenarios are mechanistically fundamentally different, ex- Copyright Ó 2014 by The American Association of Immunologists, Inc. 0022-1767/14/$16.00 plaining the different outcomes. 5448 LETTERS TO THE EDITOR Downloaded from FIGURE 1. Influence of buffer composition on the activity of the alternative pathway of complement activation in mice in the presence and the absence of the Masp1 gene products: MASP-1, MASP-3, and MAp44. (A) Rabbit erythrocyte lysis as a function of a 1.5-fold dilution series in gelatin-containing Veronal buffer (GVB) with EGTA and MgCl2 (GVB/EGTA/Mg: 5 mM barbital, 145 mM NaCl, 10 mM EGTA, 5 mM MgCl2, pH 7.4, with 0.1% [w/v] gelatin) of either wild-type C57BL/6 serum or Masp1 knockout serum. Note the narrow dynamic range in such assays. Mean and SD of duplicate http://www.jimmunol.org/ measurements. Experiment repeated with two different dilution series. GVB/EGTA/Mg 5 buffer only (i.e., background signal). H2O 5 maximal signal following hypotonic lysis. (B) C3 deposition in microtiter wells coated with the alternative pathway activator zymosan, as a function of a 2-fold dilution series of C57BL/6 serum in various buffers. Mean and SD of duplicates, experiment repeated twice. VBS/Ca, Veronal-buffered saline (5 mM barbital, 145 mM NaCl, pH 7.4) with 5 mM CaCl2 5 all complement pathways are active. VBS/EGTA/Mg, VBS with 10 mM EGTA and 5 mM MgCl2 5 only the alternative pathway is active. Boric acid/EGTA/Mg, boric acid-buffered saline (200 mM boric acid, 140 mM NaCl, pH 8.0) with 30 mM EGTA and 35 mM MgCl2 5 alternative pathway in presence of high ionic strength (as in Ref. 4). VBS/EDTA, VBS with 10 mM EDTA 5 no pathways active (i.e., background signal). (C)Asin(B), but for Masp1 knockout serum. Note the influence of high ionic strength on alternative pathway activity, especially in the Masp1 knockout mouse serum. by guest on September 25, 2021 Søren E. Degn, Jens C. Jensenius, and Steffen Thiel collagen antibody-induced model of inflammatory arthritis. J. Immunol. 185: 5598–5606. 7. Ruseva, M. M., M. Takahashi, T. Fujita, and M. C. Pickering. 2014. C3 dysregulation Department of Biomedicine, Aarhus University, DK-8000 Aarhus C, Denmark due to factor H deficiency is mannan-binding lectin-associated serine proteases Clin. Exp. Immunol. Address correspondence and reprint requests to Dr. Søren E. Degn, Department (MASP)-1 and MASP-3 independent in vivo. 176: 84–92. 8. Yamauchi, Y., J. W. Stevens, K. J. Macon, and J. E. Volanakis. 1994. Recombinant of Biomedicine, Aarhus University, Bartholin Building, Wilhelm Meyers Alle´ 4, J.
Recommended publications
  • MASP-1, a Promiscuous Complement Protease: Structure of Its Catalytic Region Reveals the Basis of Its Broad Specificity 1
    MASP-1, a promiscuous complement protease: structure of its catalytic region reveals the basis of its broad specificity 1 József Dobó 2,3* , Veronika Harmat 3† , László Beinrohr *, Edina Sebestyén *, Péter Závodszky *, Péter Gál 2* * Institute of Enzymology, Biological Research Center, Hungarian Academy of Sciences, Karolina út 29, H-1113, Budapest, Hungary † Protein Modeling Group, Hungarian Academy of Sciences, and Laboratory of Structural Chemistry and Biology, Institute of Chemistry, Eötvös Loránd University , Pázmány Péter sétány 1A, H-1117, Budapest, Hungary Running title: Structure of MASP-1 CCP1-CCP2-SP Keywords (not in the title): lectin pathway; innate immunity; modular serine protease; mannan-binding lectin; MBL-associated serine protease; MASP-2; C1r; C1s; thrombin; trypsin; factor D 1 Abstract Mannose-binding lectin (MBL)-associated serine protease-1 (MASP-1) is an abundant component of the lectin pathway of complement. The related enzyme, MASP-2 is capable of activating the complement cascade alone. Though the concentration of MASP-1 far exceeds that of MASP-2 only a supporting role of MASP-1 has been identified regarding lectin pathway activation. Several non-complement substrates, like fibrinogen and factor XIII, have also been reported. MASP-1 belongs to the C1r/C1s/MASP family of modular serine proteases, however its serine protease domain is evolutionary different. We have determined the crystal structure of the catalytic region of active MASP-1 and refined it to 2.55 Å resolution. Unusual features of the structure are: an internal salt bridge (similar to one in factor D) between the S1 Asp189 and Arg224, and a very long 60-loop.
    [Show full text]
  • By Map44 Pathway Activation in a Manner Inhibitable Pattern
    Co-Complexes of MASP-1 and MASP-2 Associated with the Soluble Pattern-Recognition Molecules Drive Lectin Pathway Activation in a Manner Inhibitable This information is current as by MAp44 of September 28, 2021. Søren E. Degn, Lisbeth Jensen, Tomasz Olszowski, Jens C. Jensenius and Steffen Thiel J Immunol 2013; 191:1334-1345; Prepublished online 19 June 2013; Downloaded from doi: 10.4049/jimmunol.1300780 http://www.jimmunol.org/content/191/3/1334 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2013/06/19/jimmunol.130078 Material 0.DC1 References This article cites 43 articles, 23 of which you can access for free at: http://www.jimmunol.org/content/191/3/1334.full#ref-list-1 Why The JI? Submit online. by guest on September 28, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Co-Complexes of MASP-1 and MASP-2 Associated with the Soluble Pattern-Recognition Molecules Drive Lectin Pathway Activation in a Manner Inhibitable by MAp44 Søren E.
    [Show full text]
  • Ncounter Human Inflammation V2 Panel Gene List
    nCounter Human Inflammation V2 Panel Gene List Official Symbol Accession Alias / Prev Symbol GO Annotation* Official Full Name Intrinsic To Plasma Membrane,Intrinsic To Membrane,Membrane Part,Membrane,Integral To Membrane,Integral To Plasma Membrane,Plasma Membrane Part,Plasma Membrane,Signal Transduction,Cell Surface Receptor Linked Signal Transduction Go 0007166,Defense Response,Inflammatory Response,Response To Stress,Response To External AGER NM_001136.3 RAGE Stimulus,Response To W advanced glycosylation end product-specific receptor Cytoplasmic Part,Membrane,Cytoplasm,Cytosol,Plasma Membrane,Regulation Of Biological Quality,Positive Regulation Of Cell Proliferation,Cell Development,Negative Regulation Of Apoptosis,Programmed Cell Death,Regulation Of Growth,Carboxylic Acid Metabolic ALOX12 NM_000697.1 12-LOX, 12S-LOX, LOG12 Process,Fatty Acid Oxidation,Negative Regulation Of Cellular Process,Regulation Of Cell arachidonate 12-lipoxygenase Defense Response,Inflammatory Response,Response To Stress,Response To External ALOX15 NM_001140.3 15-LOX-1, 15LOX-1 Stimulus,Response To Wounding,Oxidoreductase Activity arachidonate 15-lipoxygenase ALOX5 NM_000698.2 5-LO, 5-LOX, 5LPG, LOG5 Oxidoreductase Activity arachidonate 5-lipoxygenase Extracellular Region,Extracellular Region Part,Extracellular Space,Cell Cell Signaling,Cell AREG NM_001657.2 AR, CRDGF, SDGF Proliferation Go 0008283,Receptor Binding,Growth Factor Activity amphiregulin Cytoplasm,Carboxylic Acid Metabolic Process,Glutamine Family Amino Acid Metabolic Process,Amino Acid Metabolic
    [Show full text]
  • Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease
    Supplementary Online Content Ganz P, Heidecker B, Hveem K, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. doi: 10.1001/jama.2016.5951 eTable 1. List of 1130 Proteins Measured by Somalogic’s Modified Aptamer-Based Proteomic Assay eTable 2. Coefficients for Weibull Recalibration Model Applied to 9-Protein Model eFigure 1. Median Protein Levels in Derivation and Validation Cohort eTable 3. Coefficients for the Recalibration Model Applied to Refit Framingham eFigure 2. Calibration Plots for the Refit Framingham Model eTable 4. List of 200 Proteins Associated With the Risk of MI, Stroke, Heart Failure, and Death eFigure 3. Hazard Ratios of Lasso Selected Proteins for Primary End Point of MI, Stroke, Heart Failure, and Death eFigure 4. 9-Protein Prognostic Model Hazard Ratios Adjusted for Framingham Variables eFigure 5. 9-Protein Risk Scores by Event Type This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Supplemental Material Table of Contents 1 Study Design and Data Processing ......................................................................................................... 3 2 Table of 1130 Proteins Measured .......................................................................................................... 4 3 Variable Selection and Statistical Modeling ........................................................................................
    [Show full text]
  • MASP-3 Is the Exclusive Pro-Factor D Activator in Resting Blood: the Lectin and the Alternative Complement Pathways Are Fundamentally Linked
    www.nature.com/scientificreports OPEN MASP-3 is the exclusive pro- factor D activator in resting blood: the lectin and the alternative Received: 03 May 2016 Accepted: 29 July 2016 complement pathways are Published: 18 August 2016 fundamentally linked József Dobó1,*, Dávid Szakács2,*, Gábor Oroszlán1, Elod Kortvely3, Bence Kiss2, Eszter Boros2, Róbert Szász4, Péter Závodszky1, Péter Gál1 & Gábor Pál2 MASP-3 was discovered 15 years ago as the third mannan-binding lectin (MBL)-associated serine protease of the complement lectin pathway. Lacking any verified substrate its role remained ambiguous. MASP-3 was shown to compete with a key lectin pathway enzyme MASP-2 for MBL binding, and was therefore considered to be a negative complement regulator. Later, knock-out mice experiments suggested that MASP-1 and/or MASP-3 play important roles in complement pro-factor D (pro-FD) maturation. However, studies on a MASP-1/MASP-3-deficient human patient produced contradicting results. In normal resting blood unperturbed by ongoing coagulation or complement activation, factor D is present predominantly in its active form, suggesting that resting blood contains at least one pro-FD activating proteinase that is not a direct initiator of coagulation or complement activation. We have recently showed that all three MASPs can activate pro-FD in vitro. In resting blood, however, using our previously evolved MASP-1 and MASP-2 inhibitors we proved that neither MASP-1 nor MASP-2 activates pro-FD. Other plasma proteinases, particularly MASP-3, remained candidates for that function. For this study we evolved a specific MASP-3 inhibitor and unambiguously proved that activated MASP-3 is the exclusive pro-FD activator in resting blood, which demonstrates a fundamental link between the lectin and alternative pathways.
    [Show full text]
  • The Serine Protease Domain of MASP-3: Enzymatic Properties and Crystal Structure in Complex with Ecotin
    The serine protease domain of MASP-3: enzymatic properties and crystal structure in complex with ecotin. Christine Gaboriaud, Rajesh Kumar Gupta, Lydie Martin, Monique Lacroix, Laurence Serre, Florence Teillet, Gérard J Arlaud, Véronique Rossi, Nicole Thielens To cite this version: Christine Gaboriaud, Rajesh Kumar Gupta, Lydie Martin, Monique Lacroix, Laurence Serre, et al.. The serine protease domain of MASP-3: enzymatic properties and crystal structure in complex with ecotin.. PLoS ONE, Public Library of Science, 2013, 8 (7), pp.e67962. 10.1371/journal.pone.0067962. inserm-00868926 HAL Id: inserm-00868926 https://www.hal.inserm.fr/inserm-00868926 Submitted on 2 Oct 2013 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. The Serine Protease Domain of MASP-3: Enzymatic Properties and Crystal Structure in Complex with Ecotin Christine Gaboriaud1,2,3*, Rajesh Kumar Gupta1,2,3¤a, Lydie Martin1,2,3, Monique Lacroix1,2,3, Laurence Serre3,1¤b, Florence Teillet1,2,3,Ge´rard J. Arlaud1,2,3,Ve´ronique Rossi1,2,3, Nicole M. Thielens1,2,3 1 Institut de Biologie Structurale (IBS), Direction des Sciences du Vivant, Commissariat a` l’Energie Atomique et aux Energies Alternatives, Grenoble, France, 2 IBS, Centre National de la Recherche Scientifique, Grenoble, France, 3 IBS, Universite´ Grenoble Alpes, Grenoble, France Abstract Mannan-binding lectin (MBL), ficolins and collectin-11 are known to associate with three homologous modular proteases, the MBL-Associated Serine Proteases (MASPs).
    [Show full text]
  • On the Value of Therapeutic Interventions Targeting the Complement System in Acute Myocardial Infarction
    UvA-DARE (Digital Academic Repository) The inflammatory response in myocarditis and acute myocardial infarction Emmens, R.W. Publication date 2016 Document Version Final published version Link to publication Citation for published version (APA): Emmens, R. W. (2016). The inflammatory response in myocarditis and acute myocardial infarction. General rights It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons). Disclaimer/Complaints regulations If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible. UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl) Download date:02 Oct 2021 Chapter 5 On the value of therapeutic interventions targeting the complement system in acute myocardial infarction Reindert Emmens, Diana Wouters, Sacha Zeerleder, Marieke van Ham, Hans Niessen, Paul Krijnen Submitted for publication 81 SUMMARY The complement system plays an important role in the inflammatory response subsequent to acute myocardial infarction (AMI), by actively increasing cell death of cardiomyocytes beyond the primary infarcted area.
    [Show full text]
  • Human Map44 HK359
    Human MAp44 HK359 Edition 05-13 ELISA KIT PRODUCT INFORMATION & MANUAL Read carefully prior to starting procedures! For use in laboratory research only Not for clinical or diagnostic use Note that this user protocol is not lot-specific and is representative for the current specifications of this product. Please consult the vial label and the Certificate of Analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions. For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product. TABLE OF CONTENTS Page 1. Intended use ..................................................................................................................2 2. Introduction ....................................................................................................................2 3. Kit features ....................................................................................................................2 4. Protocol overview ..........................................................................................................3 5. Kit components and storage instructions .......................................................................4 Materials required but not provided 4 6. Warnings and precautions .............................................................................................5
    [Show full text]
  • Strategies of Targeting Alternative and Lectin Pathway Components in Complement- Mediated Diseases
    REVIEW published: 08 August 2018 doi: 10.3389/fimmu.2018.01851 Be on Target: Strategies of Targeting Alternative and Lectin Pathway Components in Complement- Mediated Diseases József Dobó, Andrea Kocsis and Péter Gál* Institute of Enzymology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary The complement system has moved into the focus of drug development efforts in the last decade, since its inappropriate or uncontrolled activation has been recognized in many diseases. Some of them are primarily complement-mediated rare diseases, such as paroxysmal nocturnal hemoglobinuria, C3 glomerulonephritis, and atypical hemolytic uremic syndrome. Complement also plays a role in various multifactorial diseases that affect millions of people worldwide, such as ischemia reperfusion injury (myocardial infarction, stroke), age-related macular degeneration, and several neurodegenerative disorders. In this review, we summarize the potential advantages of targeting various Edited by: complement proteins with special emphasis on the components of the lectin (LP) and Nicole Thielens, UMR5075 Institut de Biologie the alternative pathways (AP). The serine proteases (MASP-1/2/3, factor D, factor B), Structurale (IBS), France which are responsible for the activation of the cascade, are straightforward targets of Reviewed by: inhibition, but the pattern recognition molecules (mannose-binding lectin, other collectins, Cordula M. Stover, and ficolins), the regulatory components (factor H, factor I, properdin), and C3 are also University of Leicester, United Kingdom subjects of drug development. Recent discoveries about cross-talks between the LP Maciej Cedzynski, and AP offer new approaches for clinical intervention. Mannan-binding lectin-associated Institute for Medical Biology (PAN), Poland serine proteases (MASPs) are not just responsible for LP activation, but they are also Christian Drouet, indispensable for efficient AP activation.
    [Show full text]
  • Role of Complement in Diabetes
    This is a repository copy of Role of complement in diabetes. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/151783/ Version: Accepted Version Article: Ajjan, RA and Schroeder, V (2019) Role of complement in diabetes. Molecular Immunology, 114. pp. 270-277. ISSN 0161-5890 https://doi.org/10.1016/j.molimm.2019.07.031 (c) 2019, Elsevier Ltd. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/ Reuse This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can’t change the article in any way or use it commercially. More information and the full terms of the licence here: https://creativecommons.org/licenses/ Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Molecular Immunology, Special Issue EMCHD 2019 Review Article Role of Complement in Diabetes Ramzi A. Ajjan a, Verena Schroeder b* a Leeds Institute for Cardiovascular and Metabolic Medicine, School of Medicine, University of Leeds, Leeds, United Kingdom b Experimental Haemostasis Group, Department for BioMedical Research (DBMR), University of Bern, Bern, Switzerland * Corresponding author: Verena Schroeder Experimental Haemostasis Group Department for BioMedical Research (DBMR) University of Bern Murtenstrasse 40 3008 Bern Switzerland Tel.: +41 31 632 9618 E-mail: [email protected] 1 Abstract Accumulating evidence suggests a role for the complement system in the pathogenesis of diabetes and the vascular complications that characterise this condition.
    [Show full text]
  • MASP-1 and MASP-2 Do Not Activate Pro-FD in Resting Human
    MASP-1 and MASP-2 do not activate pro-FD in resting human blood, while MASP-3 is a potential activator: kinetic analysis involving specific MASP-1 and MASP-2 inhibitors Gábor Oroszlán *, Elod Kortvely †, Dávid Szakács ‡, Andrea Kocsis *, Sascha Dammeier §, Anne Zeck ¶, Marius Ueffing †,§, Péter Závodszky *, Gábor Pál ‡ , Péter Gál *2, József Dobó *2 * Institute of Enzymology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Magyar tudósok krt. 2, H-1117, Budapest, Hungary † Institute for Ophthalmic Research, University of Tübingen, Röntgenweg 11, 72076 Tübingen, Germany ‡ Department of Biochemistry, Eötvös Loránd University, 1/C Pázmány Péter street, H-1117, Budapest, Hungary § Institute for Ophthalmic Research, Medical Proteome Center, University of Tübingen, Nägelestrasse 5, 72074 Tübingen, Germany ¶ Natural and Medical Sciences Institute at the University of Tübingen, Department of Bioanalytics, Markwiesenstrasse 55, 72770 Reutlingen, Germany 2 Address correspondence and reprint request to J. Dobó, and/or P. Gál, Institute of Enzymology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Magyar tudósok krt. 2, H- 1117, Budapest, Hungary, e-mail: [email protected] (J.D.), or [email protected] (P.G.), phone: +36-1-3826768, fax: +36-1-3826295 Running title: Kinetics of pro-FD activation Keywords (not in the title): lectin pathway; innate immunity; mannan-binding lectin; MBL- associated serine protease; thrombin; trypsin 1 Abstract It had been thought that complement factor D (FD) is activated at the site of synthesis and only FD lacking a propeptide is present in blood. The serum of MASP-1/3(-/-) mice contains pro-FD and has markedly reduced alternative pathway activity.
    [Show full text]
  • Targeting of Liver Mannan-Binding Lectin
    Targeting of Liver Mannan-Binding Lectin−Associated Serine Protease-3 with RNA Interference Ameliorates Disease in a Mouse Model of Rheumatoid Arthritis Downloaded from Nirmal K. Banda, Dhruv Desai, Robert I. Scheinman, Rasmus Pihl, Hideharu Sekine, Teizo Fujita, Vibha Sharma, Annette G. Hansen, Peter Garred, Steffen Thiel, Anna Borodovsky and V. Michael Holers http://www.immunohorizons.org/ ImmunoHorizons 2018, 2 (8) 274-295 http://www.immunohorizons.org/ doi: https://doi.org/10.4049/immunohorizons.1800053 http://www.immunohorizons.org/content/2/8/274 This information is current as of September 25, 2021. Supplementary http://www.immunohorizons.org/content/suppl/2018/09/14/2.8.274.DCSupp Material lemental by guest on September 25, 2021 References This article cites 60 articles, 25 of which you can access for free at: by guest on September 25, 2021 http://www.immunohorizons.org/content/2/8/274.full#ref-list-1 Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://www.immunohorizons.org/alerts ImmunoHorizons is an open access journal published by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 All rights reserved. ISSN 2573-7732. RESEARCH ARTICLE Innate Immunity Targeting of Liver Mannan-Binding Lectin–Associated Serine Protease-3 with RNA Interference Ameliorates Disease in a Mouse Model of Rheumatoid Arthritis Nirmal K. Banda,*,1 Dhruv Desai,† Robert I. Scheinman,‡ Rasmus Pihl,§ Hideharu Sekine,{ Teizo Fujita,{ Vibha Sharma,|| Downloaded from Annette
    [Show full text]